COPD in Primary Care: GOLD Groups, Inhaler Choice and When to Add What

COPD management in primary care follows the GOLD 2026 report in three moves: confirm the diagnosis with spirometry, assign the patient to Group A, B or E from symptoms and exacerbation history, and match the initial inhaler to that group. Group A starts a bronchodilator, Group B starts a LABA plus LAMA, and Group E starts a LABA plus LAMA with triple therapy (adding an inhaled corticosteroid) considered when blood eosinophils are 300 cells/microL or higher. After that, the provider adds therapy only for a named problem, persistent dyspnea or further exacerbations, using eosinophil counts to decide whether ICS, roflumilast, azithromycin or a biologic comes next.

Assessment: who to test and how the diagnosis is made

Suspect COPD in any adult with chronic dyspnea, cough or sputum, recurrent lower respiratory infections, and a history of exposure: tobacco smoke (including vaping and cannabis), occupational dusts and fumes, biomass smoke, or early-life problems such as prematurity. GOLD 2026 expands case finding, including through lung cancer screening programs.

Spirometry is required. A post-bronchodilator FEV1/FVC below 0.70 confirms persistent airflow obstruction in the right clinical context. A clinical picture without spirometry is not a diagnosis, and a normal ratio with symptoms points elsewhere (or to pre-COPD and PRISm, preserved ratio impaired spirometry, which GOLD tracks but does not treat as COPD).

Additional baseline work-up:

• Alpha-1 antitrypsin level once in every patient with COPD, especially younger patients or those with lower-lobe emphysema or a family history.
• Pulse oximetry at rest; arterial blood gas if SpO2 is low.
• Chest imaging to exclude other disease and to screen for lung cancer where eligible.
• Complete blood count with eosinophils, which now shapes ICS decisions.
• Comorbidities: cardiovascular disease, osteoporosis, anxiety and depression, sleep apnea, lung cancer.

Two separate scores: GOLD grade and GOLD group

The exam repeatedly tests whether you can keep these apart. The grade describes the lungs; the group decides the treatment.

The ABE tool combines symptom burden with exacerbation history over the previous year. Symptoms are measured with the mMRC dyspnea scale or the CAT (renamed the Chronic Airways Assessment Test, CAAT, in recent GOLD materials).

The 2026 change matters on the exam: GOLD 2023 to 2025 placed a patient in Group E after two or more moderate exacerbations or one leading to hospitalization. GOLD 2026 lowers the threshold to one or more moderate or severe exacerbations in the previous year. A moderate exacerbation is one treated with oral corticosteroids, antibiotics or both; a severe one requires hospitalization or an emergency visit.

Initial pharmacologic treatment by group

Three principles sit behind the table. Dual long-acting bronchodilation is the default for anyone symptomatic or at risk. GOLD states that single-inhaler therapy may be more convenient and effective than multiple inhalers and improves adherence. And LABA plus ICS without a LAMA is not encouraged in COPD; if ICS is indicated, it is given as triple therapy.

Representative long-acting agents (generic names) include LAMAs tiotropium, umeclidinium, glycopyrrolate and aclidinium, and LABAs salmeterol, formoterol, olodaterol and vilanterol, available in fixed-dose dual and triple combinations. Doses follow product labeling; for example, tiotropium is 18 mcg once daily by dry-powder inhaler or 5 mcg once daily (two 2.5 mcg puffs) by soft-mist inhaler.

Choosing the device, not just the drug

The device is part of the prescription. A dry-powder inhaler needs a fast, forceful inspiration; a frail patient with severe airflow limitation may not generate enough inspiratory flow. A pressurized metered-dose inhaler needs coordination of actuation with a slow breath, which a spacer helps. Soft-mist inhalers or nebulizers suit patients who cannot manage either. Before any escalation, GOLD asks the provider to watch the patient use the device and confirm adherence. Switching device or molecule is itself a listed option for persistent dyspnea.

Follow-up: when to add what

At follow-up, GOLD says to continue current treatment unless dyspnea or exacerbations require optimization. If both are present, follow the exacerbation pathway.

Patients already on LABA plus ICS: if they have exacerbations, consider escalating to triple therapy (eosinophils guide this); if they have no relevant exacerbation history and symptoms dominate, consider changing to LABA plus LAMA.

ICS de-escalation is considered when pneumonia or other considerable side effects occur. GOLD warns that withdrawal is more likely to be followed by exacerbations when eosinophils are 300 cells/microL or higher.

Roflumilast starts at 250 mcg daily for four weeks, then 500 mcg daily, to improve tolerance (per labeling); weight loss, diarrhea and psychiatric effects are the issues to monitor. Long-term azithromycin carries risks of QT prolongation, hearing loss and resistance; obtain an ECG and review interacting drugs first. Confirm azithromycin dosing in the current report.

Non-pharmacologic care that every plan includes

• Smoking cessation at every visit, with pharmacotherapy (varenicline, bupropion, nicotine replacement) plus counseling.
• Pulmonary rehabilitation for symptomatic patients and after an exacerbation (GOLD evidence A).
• Vaccines: influenza, COVID-19, pneumococcal and RSV for patients with COPD, plus Tdap and zoster per national schedules.
• Long-term oxygen when resting PaO2 is 55 mm Hg or lower or SaO2 is 88 percent or lower, or PaO2 55 to 60 mm Hg with pulmonary hypertension, peripheral edema suggesting heart failure, or polycythemia (confirm the exact secondary criteria in the current report).
• A written action plan, physical activity, nutrition, and advance care planning in severe disease.

Managing an exacerbation in the clinic

An exacerbation is a worsening of dyspnea, cough or sputum over less than 14 days. Assess severity first: respiratory rate, oxygen saturation, use of accessory muscles, mental status, and ability to manage at home.

Outpatient treatment: increase short-acting bronchodilators, give prednisone 40 mg daily for 5 days (supported by the REDUCE trial and GOLD), and add an antibiotic when there is increased sputum purulence plus increased dyspnea or sputum volume, usually for 5 to 7 days. Choice of antibiotic follows local resistance patterns; confirm specific agents in the current report. Review within about one to four weeks, and step up maintenance therapy using the follow-up table, because one moderate exacerbation now defines Group E.

Admission or emergency referral triggers: severe symptoms such as sudden worsening of resting dyspnea, high respiratory rate, falling oxygen saturation, confusion or drowsiness; acute respiratory failure; new signs such as cyanosis or peripheral edema; failure to respond to initial treatment; serious comorbidities; or inadequate home support.

Referral to pulmonology

Refer when the diagnosis is uncertain, when COPD appears before about age 40 or alpha-1 antitrypsin deficiency is found, when exacerbations continue despite optimized triple therapy, when a biologic, lung volume reduction or transplant evaluation is being considered, when oxygen needs are complex, or when lung function declines rapidly.

Patient and caregiver education

• Inhaler technique demonstrated and observed at every visit, with the caregiver present if the caregiver helps with devices.
• The difference between the maintenance inhaler, used daily, and the rescue inhaler.
• Early recognition of an exacerbation: more breathlessness, more sputum, a change in sputum color, and when to start the action plan or call.
• Rinse the mouth after ICS; report fever or new cough (pneumonia risk on ICS).
• Pulmonary rehabilitation is treatment, not an optional extra.

How the exam tests this

• Grade versus group. An item gives FEV1 45 percent predicted (GOLD 3) with no exacerbations and an mMRC of 1; the patient is Group A, not "severe COPD needing triple therapy."
• The 2026 Group E threshold. One moderate exacerbation treated with prednisone in the past year now means Group E. Older study resources still say two.
• ICS for everyone. Options that start ICS-LABA as first-line therapy, or add ICS without checking eosinophils, are distractors.
• Eosinophil numbers. 300 cells/microL supports ICS at the start (Group E) or after an exacerbation on one bronchodilator; 100 cells/microL is the cut-off for adding ICS on LABA plus LAMA.
• Roflumilast criteria. FEV1 under 50 percent plus chronic bronchitis plus exacerbations; it is not a bronchodilator and does not treat dyspnea.
• Technique first. A vignette that mentions trouble using the inhaler wants the device fixed, not a new drug.
• Exacerbation steroids. Prednisone 40 mg for 5 days, not a 14-day taper.

Practice question

A 66-year-old man with COPD, a 45 pack-year history and no smoking for three years, uses umeclidinium-vilanterol once daily with correct technique. Post-bronchodilator FEV1 is 58 percent predicted. His mMRC score is 2. In the past year he had two exacerbations treated in the clinic with prednisone and an antibiotic and no hospitalizations. He has no history of asthma. Blood eosinophil count is 240 cells/microL. Which of the following is the most appropriate change to his maintenance therapy?

• A. Add roflumilast.
• B. Switch to fluticasone-salmeterol.
• C. Add an inhaled corticosteroid as a single-inhaler triple therapy.
• D. Add daily oral theophylline.

Answer: C. He is having exacerbations on LABA plus LAMA with eosinophils of 240 cells/microL, which is above the GOLD threshold of 100 for adding ICS, so escalation to triple therapy in a single inhaler is the next step. Roflumilast (A) is reserved for patients with FEV1 under 50 percent and chronic bronchitis, particularly with eosinophils under 100; his FEV1 is 58 percent and no chronic bronchitis is described. Fluticasone-salmeterol (B) removes the LAMA and moves him to LABA plus ICS, which GOLD does not encourage in COPD. Theophylline (D) has a narrow therapeutic window, many interactions and little role in current GOLD escalation.

Key points

Related NPPace guides

• Outpatient Community-Acquired Pneumonia: Who Goes Home, Which Antibiotic and Follow-Up
• Sore Throat in the Clinic: Centor Scoring, When to Test for Strep and What to Prescribe
• UTI Antibiotic Choices and Durations: Cystitis, Pyelonephritis, Men, Pregnancy and Recurrence
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?